4.2 Patient Factors: Adherence, Efficacy & Safety

4.2 Patient Factors: Adherence, Efficacy & Safety

Quick Answer: Medicines only work if patients can obtain, understand, take, and tolerate them. Assess beliefs, literacy, cost, polypharmacy burden, and physical/cognitive barriers; separate intentional from unintentional non-adherence; then match supports (simplification, dose administration aids, reminders, device training) and monitor safety and goals that matter to the patient.

Patient-centred medication management under Standard 3.1 is not only about choosing the right molecule. It is about whether the plan will work in this person’s life.

Why “non-compliance” language fails

Older training language blamed patients for “not complying.” Contemporary practice treats adherence as a shared outcome of medicine design, counselling quality, social determinants, and health system access. Intern Written scenarios often hide the real barrier behind a vague “not taking tablets regularly.” Your job is to find which barrier.

Beliefs and illness perceptions

Health beliefs strongly predict intentional non-adherence:

• “I feel fine, so I don’t need blood pressure tablets.”
• “Antibiotics didn’t work last time, so I’ll stop early this time.”
• “Natural products are safer than chemicals.”
• “My relative had a bad reaction to that drug, so I won’t start.”
• “Steroid inhalers are dangerous if used every day.” (common asthma misconception)

Counselling implication: Elicit beliefs before correcting them. Ask: “What concerns do you have about this medicine?” and “What do you already know about why it was prescribed?” Motivational, non-judgemental dialogue outperforms lectures.

Link benefit to the patient’s values: stroke prevention for a grandparent who wants to remain independent; fewer night symptoms for a parent who needs sleep; staying at work for someone with financial pressure.

Health literacy

Health literacy is the ability to obtain, understand, and use health information. Low literacy is common and not visible from appearance or English fluency alone.

Clues:

• Incomplete forms, “forgot glasses,” reverse prescription directions
• Inability to explain what a medicine is for after counselling
• Confusion between look-alike packs or similar brand names
• Nodding without teach-back success

Practical supports:

• Plain language, short sentences, one message at a time
• Teach-back: “Just to be sure I explained it clearly, how will you take this?”
• Demonstrate devices; avoid jargon (say “water tablet” and the medicine name if that helps, then standardise to the label name)
• Written plans with large font; pictograms where appropriate
• Involve a carer with consent when capacity or literacy limits safe use

Never equate limited English with limited intelligence; use qualified interpreters when needed (see 4.4).

Cost and access barriers

Even with PBS subsidies, cost remains a barrier: multiple co-payments, non-PBS items, devices, and travel to pharmacy or clinic. Patients may ration medicines (e.g. take “every other day”), share medicines, or delay initiation.

Assessment questions:

• “Do you ever skip doses because of cost?”
• “Which medicines would you stop first if money were tight?” (reveals priorities and risk)

Pharmacist responses within scope:

• Check PBS eligibility, Safety Net thresholds, and whether a more affordable equivalent or formulary option exists via prescriber discussion
• Prefer combination products or longer supply intervals when clinically appropriate and lawful
• Avoid starting expensive non-essential complementary products that compete with essential therapy budgets
• Flag social-work or GP support for broader hardship — do not invent benefits, but do not ignore cost as a clinical problem

Polypharmacy burden

Polypharmacy increases non-adherence, interactions, and ADRs. Burden is not only tablet count — it includes timing complexity (with/without food, multiple times daily), monitoring requirements, and cognitive load.

A patient-centred plan sometimes improves outcomes by removing medicines more than by adding adherence tools to a chaotic regimen.

Cognitive and physical barriers

Cognitive: dementia, delirium, depression, intellectual disability, substance intoxication. Patients may not remember counselling, may double-dose, or may be vulnerable to exploitation.

Physical: vision impairment, arthritis limiting bottle opening or inhaler actuation, dysphagia, tremor, limited reach for topical sites.

Responses:

• Easy-open containers only when child safety is not required, or transfer strategies with carers
• Large-print labels, multi-compartment aids (see tools below)
• Liquid or dispersible forms if appropriate and stable
• Spacer devices, breath-actuated inhalers, or carer-administered options after clinical review
• Home medicines review / residential care processes where eligible and indicated

Capacity and consent rules still apply — supporting adherence never means covert dosing without legal and ethical authority.

Intentional vs unintentional non-adherence

This distinction drives the intervention.

Exam tip: If a scenario shows a patient who stopped a statin because of “muscle aches” fear after reading online, a dose administration aid alone is the wrong primary answer. If a patient with good insight forgets midday doses at work, regimen redesign beats another pamphlet on cardiovascular risk.

Tools that support adherence

Match tool to barrier:

1. Regimen simplification — fewest daily dosing times; align medicines to morning routine when possible; stop unnecessary “as well as” products.
2. Dose administration aids (DAAs / blister packs) — useful for multi-dose complexity and carer oversight; limitations include mid-cycle changes, stability of some medicines outside original packs, and false reassurance if intentional non-adherence persists.
3. Reminders — phone alarms, apps, SMS, dosette with visual cues, pairing with meals/teeth brushing.
4. Education & written action plans — asthma/COPD plans, sick-day plans for diabetes medicines where appropriate, antibiotic duration calendars.
5. Device training — inhalers, insulin pens, epinephrine autoinjectors; recheck technique regularly; poor technique looks like “drug failure.”
6. Follow-up — short call-backs after new high-risk starts; review residual tablets as a non-judgemental adherence signal.

Caution with DAAs: Some medicines are unsuitable for repacking (e.g. certain hygroscopic, light-sensitive, or original-pack-required products — check product and professional guidance). Always reconcile the pack contents when prescriptions change.

Safety as a patient factor

Adherence to an unsafe regimen is not success. Patient-centred safety screening includes:

• Falls risk: sedatives, anticholinergics, antihypertensives causing postural drop, opioids, alcohol co-use
• Confusion / delirium risk: anticholinergics, high-dose opioids, benzodiazepines, corticosteroid neuropsychiatric effects
• Hypoglycaemia: insulin, sulfonylureas — especially in elderly or irregular eaters
• Bleeding: anticoagulants, antiplatelets, NSAID combinations
• Sedation & driving: counsel on impairment and legal responsibilities
• Anticholinergic burden: constipation, urinary retention, dry mouth, cognitive worsening

Ask about near-misses: “Have you felt dizzy standing up?” “Any night-time wandering or new confusion?” “Any black stools or unusual bruising?”

Efficacy monitoring with patient goals

Efficacy is not only a lab number. Define success with the patient:

When efficacy seems lacking, reverse-engineer: wrong drug/dose, non-adherence, poor device technique, interacting medicines, wrong diagnosis, unrealistic timeframe (e.g. expecting full antidepressant effect in three days).

Plan review points at initiation: what improvement is expected and when; what side effects should prompt contact; what constitutes failure needing prescriber review.

Shared decision-making in practice

A patient may accept a slightly less “guideline-perfect” regimen that they will actually take over a theoretically superior plan they will abandon. Document trade-offs when advising prescribers: “Patient unable to manage thrice-daily dosing; once-daily option preferred if clinically acceptable.”

Mini-cases for exam reasoning

Case 1 — Intentional: Woman of reproductive age stops isotretinoin-related counselling partner medicine because she “isn’t sexually active this month.” Address pregnancy prevention requirements and legal/PBS program obligations with clear, respectful education — not a blister pack.

Case 2 — Unintentional: Older man on five evening medicines including a diuretic wakes nocturic and skips evening doses. Timing review (diuretic earlier) may restore adherence better than admonishment.

Case 3 — Safety vs adherence: Patient perfectly adherent to amitriptyline for neuropathic pain now has recurrent falls. Efficacy for pain does not justify ignoring falls — review anticholinergic/sedative burden and alternatives with the prescriber.

Patient factors turn a correct pharmacological choice into a workable, monitored care plan — the essence of Standard 3.1.